Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BrightGene Copying Gilead's Remdesivir, Says It Wants to In-License the Anti-Viral

publication date: Feb 12, 2020

BrightGene Bio-Medical of Suzhou has synthesized the API of remdesivir, a Gilead drug that has started China Phase III trials to treat patients infected with the COVID-19 virus. Gilead owns IP on the drug, so the announcement produced worry that BrightGene may infringe on Gilead's patent. BrightGene said it already has mass-produced remdesivir's API and is in the process of turning it into finished doses. The company further declared it intends to license the drug from Gilead, though it isn't clear that any negotiations have begun. More details....

Stock Symbols: (SHA: 688166) (NSDQ: GILD)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.